Free tool
FAERS Monitor: Solosec
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209363 or its brand name (Solosec, Secnidazole). Reports on generic versions are filed under their own applications.
Reports
282
Serious
66
23% of reports
Hospitalization
22
Death reported
3
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- vomiting78
- nausea51
- drug ineffective31
- diarrhoea23
- wrong technique in product usage process22
- product taste abnormal21
- headache20
- dysgeusia18
- abdominal pain17
- malaise13
- no adverse event13
- abdominal discomfort11
- chromaturia11
- bacterial vaginosis10
- foetal exposure during pregnancy10
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 1 |
| 2008 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 3 |
| 2016 | 1 |
| 2018 | 54 |
| 2019 | 108 |
| 2020 | 64 |
| 2021 | 16 |
| 2022 | 10 |
| 2023 | 11 |
| 2024 | 3 |
| 2025 | 4 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,877 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| bacterial vaginosisSignal | 10 | 480.1 | 260.7 | 4,287 |
| product taste abnormalSignal | 21 | 115.9 | 76.7 | 2,276 |
| chromaturiaSignal | 11 | 36.4 | 20.4 | 344 |
| dysgeusiaSignal | 18 | 18.1 | 11.6 | 274 |
| vomitingSignal | 78 | 12.4 | 10.2 | 822 |
| foetal exposure during pregnancySignal | 10 | 9.2 | 5.0 | 65 |
| wrong technique in product usage processSignal | 22 | 8.1 | 5.4 | 131 |
| abdominal painSignal | 17 | 5.5 | 3.4 | 58 |
| no adverse eventSignal | 13 | 5.4 | 3.1 | 42 |
| abdominal discomfortSignal | 11 | 4.9 | 2.7 | 31 |
| nauseaSignal | 51 | 4.8 | 3.7 | 156 |
| diarrhoeaSignal | 23 | 2.7 | 1.8 | 23 |
| headacheSignal | 20 | 2.4 | 1.6 | 15 |
| malaiseSignal | 13 | 2.2 | 1.3 | 8 |
| drug ineffective | 31 | 1.8 | 1.3 | 10 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.